Identification of a small peptide targeting epithelial adhesion molecule EpCAM
ZHU Yichao1 MA Xiaowen2,3 HE Lei2 ZHOU Jiming2,4 PANG Zhijun2 ZHANG Xinlei2 MAO Zhuang1 LI Meng2
1.The Brigade of Undergraduates, the Fourth Military Medical University, Shaanxi Province, Xi′an 710032, China;
2.School of Pharmacy, the Fourth Military Medical University, Shaanxi Province, Xi′an 710032, China;
3.Department of Pharmacology, General Hospital of Ji′nan Military Region, Shandong Province, Ji′nan 250000, China;
4.Department of Cardiology, the 153rd Central Hospital of People′s Liberation Army, He′nan Province, Zhengzhou 450000, China
Abstract：Objective To find the molecular target of an esophagus adenocarcinoma specific binding peptide (SNF*). Methods Pull Down and Mass Spectrum were used to identify the potential target; molecular docking, Western blot, laser scanning confocal microscopy, flow cytomertry, RNA interference and gene transfection were used to verify the target of SNF*. Results Epithelial adhesion molecule (EpCAM) was the potential target of SNF*. SNF* specifically bound with EpCAM which overexpressed in colon cancer cells and tissues. Conclusion Except esophagus adenocarcinoma, SNF* can be used in the early diagnosis and targeted therapy in colorectal cancer with high EpCAM expression.
[1] Dey N，Williams C，Leyland-Jones B. Mutation matters in precision medicine：A future to believe in [J]. Cancer Treat Rev，2017，55：136-149.
[2] Roukos DH. Spatiotemporal diversification of intrapatient genomic clones and early drug development [J]. Drug Discov Today，2017，22（8）：1148-1164.
[3] Ahmadyousefi Y，Malih S. Nucleic acid aptamers in diagnosis of colorectal cancer [J]. Biochimie，2018，9：2234-2237.
[4] Ryan JM，Wasser JS，Adler AJ，et al. Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit [J]. Expert Opin Biol Ther，2016，16（5）：655-674.
[5] Gorovits B，Krinos-Fiorotti C. Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake [J]. Cancer Immunol Immunother，2013，62（2）：217-223.
[6] Le Joncour V，Laakkonen P. Seek & Destroy，use of targeting peptides for cancer detection and drug delivery [J]. Bioorg Med Chem，2018，26（10）：2797-2806.
[7] Li M，Anastassiades CP，Joshi B，et al. Affinity peptide for targeted detection of dysplasia in Barrett′s esophagus [J]. Gastroenterology，2010，139（5）：1472-1480.
[8] Litvinov SV，Balzar M，Winter MJ. Epithelial cell adhesion molecule（Ep-CAM）modulates cell-cell interactions [J]. J Cell Biol，1997，139（5）：1337-1348.
[9] Münz M，Kieu C，Mack B. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation [J]. Oncogene，2004，23（34）：5748-5758.
[10] Maetzel D，Denzel S，Mack B. Nuclear signalling by tumour-associated antigen EpCAM [J]. Nat Cell Biol，2009， 11（2）：162-171.
[11] Atlas of Genetics and Cytogenetics in Oncology and Haematology [EB/OL].（2018-09-26）. http：//AtlasGeneticsOncology.org/Genes/TACSTD1ID42459ch2p21.html.
[12] Tayama S，Motohara T，Narantuya D. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients [J]. Oncotarget，2017，8（27）：44312-44325.
[13] van der Gun BT，Melchers LJ，Ruiters MH. EpCAM in carcinogenesis：the good，the bad or the ugly [J]. Carcinogenesis，2010，31（11）：1913-1921.
[14] Bokemeyer C，Stein A. A phase Ⅱ study of catumaxomab administered intra- and postoperatively in primarily resectable gastric cancer [J]. Gastric Cancer，2015，18（4）：833-842.
[15] Fossati M，Buzzonetti A，Monego G. Immunological changes in the ascites of cancer patients after intraperitoneal administration of the antibody catumaxomab [J]. Gynecol Oncol，2015，138（2）：343-351.
[16] Joshi BP，Wang TD. Gastrointestinal imaging in 2015：Emerging trends in endoscopic imaging [J]. Nat Rev Gastroenterol Hepatol，2016，13（2）：72-73.
[17] Craik DJ，Fairlie DP，Liras S，et al. The future of peptide-based drugs [J]. Chem Biol Drug Des，2013，81（1）：136-147.
[18] Thundimadathil J. Cancer treatment using peptides：current therapies and future prospects [J]. J Amino Acids，2012，2012：967347.
[19] Akerman ME，Chan WC，Laakkonen P，et al. Nanocrystal targeting in vivo [J]. Proc Natl Acad Sci U S A，2002，99（20）：12617-12621.
[20] Laakkonen P，Akerman ME，Biliran H，et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells [J]. Proc Natl Acad Sci U S A，2004， 101（25）：9381-9386.
2019, Vol. 16 
京公网安备 11010502046598号